Randomized, Double-blind, Placebo-controlled, Multi-center Study of Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients of NSCLC With Brain Metastases of Driven Gene-negative and Not Received Systemic Chemotherapy
Latest Information Update: 07 May 2024
At a glance
- Drugs Camrelizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
- Indications Brain metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 26 Feb 2021 New trial record